Skip to main content
Caplight Logo









Evox Therapeutics

Evox Therapeutics

Private
OxfordHealthcare & Life Scienceshttps://www.evoxtherapeutics.com/

Last Round

Series C

Feb 18, 2021

Total Funding Raised

$168.25M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Evox Therapeutics is a biotechnology company that develops exosome-based therapeutics for the treatment of severe rare, neurological, and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

exosome therapeuticsdrug delivery platformgene editingextracellular vesiclestargeted drug deliverybiotech platformrare disease therapyexosome engineeringblood-brain barrierbiopharma partnershipexosome techdelivery vehicletherapeutic payloaddrug delivery techbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Evox Therapeutics Comparables

Compare Evox Therapeutics with similar companies based on industry and business-model similarity.

Evox Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ILIAS Biologics Inc.
84%
EXO Biologics
77%
VivaZome Therapeutics
77%

Evox Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 18, 2021
Convertible DebtJun 9, 2020
GrantMar 22, 2019
GrantNov 13, 2018
GrantOct 1, 2018
Series B
Sep 3, 2018

Evox Therapeutics Investors

Notable investors and investment history

Evox Therapeutics investors
InvestorRounds
Redmile GroupSeries B, Series C
Innovate UKGrant
UK governmentGrant
GVSeries B, Series C
Cowen Private InvestmentsSeries B, Series C
Duchenne UKGrant
Oxford Science EnterprisesSeries B, Series C, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 100% MoM to 5.5K.

  • Mar 22, 2019

    $2M grant received from Innovate UK and UK government.

Evox Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Evox Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Evox Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range37
Year Founded2016
Last FundingFeb 18, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?